Is Sonoma Pharmaceuticals Stock a Good Investment?
Sonoma Pharmaceuticals Investment Advice | SNOA |
- Examine Sonoma Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sonoma Pharmaceuticals' leadership team and their track record. Good management can help Sonoma Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Sonoma Pharmaceuticals' business and its evolving consumer preferences.
- Compare Sonoma Pharmaceuticals' performance and market position to its competitors. Analyze how Sonoma Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Sonoma Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sonoma Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sonoma Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sonoma Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Sonoma Pharmaceuticals Stock
Researching Sonoma Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sonoma Pharmaceuticals recorded a loss per share of 0.99. The entity last dividend was issued on the 20th of June 2019. The firm had 1:20 split on the 30th of August 2024.
To determine if Sonoma Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sonoma Pharmaceuticals' research are outlined below:
| Sonoma Pharmaceuticals generated a negative expected return over the last 90 days | |
| Sonoma Pharmaceuticals has high historical volatility and very poor performance | |
| Sonoma Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.73 M. Net Loss for the year was (4.83 M) with profit before overhead, payroll, taxes, and interest of 4.48 M. | |
| Sonoma Pharmaceuticals currently holds about 5.59 M in cash with (2.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8. | |
| Sonoma Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Sonoma Pharmaceuticals ends agreement with EMC Pharma |
Sonoma Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sonoma Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sonoma Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 19th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of June 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Sonoma Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Sonoma Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2023-11-13 | 2023-09-30 | -0.24 | -0.29 | -0.05 | 20 | ||
2024-06-17 | 2024-03-31 | -0.17 | -0.07 | 0.1 | 58 | ||
2024-02-08 | 2023-12-31 | -0.21 | -0.08 | 0.13 | 61 | ||
2023-08-10 | 2023-06-30 | -0.12 | -0.2796 | -0.1596 | 133 | ||
2019-11-14 | 2019-09-30 | -1.18 | -0.91 | 0.27 | 22 | ||
2021-02-16 | 2020-12-31 | -0.72 | -0.32 | 0.4 | 55 | ||
2024-11-11 | 2024-09-30 | -1 | -0.59 | 0.41 | 41 |
Know Sonoma Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sonoma Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sonoma Pharmaceuticals backward and forwards among themselves. Sonoma Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Sonoma Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-06-30 | 2.3 K | U.s. Bancorp | 2024-06-30 | 500 | Advisor Group Holdings, Inc. | 2024-06-30 | 200 | Bank Of America Corp | 2024-06-30 | 172 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 86.0 | Wells Fargo & Co | 2024-06-30 | 33.0 | Hanson Mcclain Inc | 2024-09-30 | 3.0 | Hbc Financial Services, Pllc | 2024-06-30 | 2.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 195.2 K | Geode Capital Management, Llc | 2024-06-30 | 86.6 K |
Sonoma Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.9 M.Market Cap |
|
Sonoma Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.34) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.33) | (0.34) | |
| Return On Equity | (0.79) | (0.75) |
Determining Sonoma Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Sonoma Pharmaceuticals is a good buy. For example, gross profit margin measures Sonoma Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sonoma Pharmaceuticals' profitability and make more informed investment decisions.
Sonoma Pharmaceuticals' Earnings Breakdown by Geography
Please note, the presentation of Sonoma Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sonoma Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sonoma Pharmaceuticals' management manipulating its earnings.
Evaluate Sonoma Pharmaceuticals' management efficiency
Sonoma Pharmaceuticals has return on total asset (ROA) of (0.1959) % which means that it has lost $0.1959 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7465) %, meaning that it created substantial loss on money invested by shareholders. Sonoma Pharmaceuticals' management efficiency ratios could be used to measure how well Sonoma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.34. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Sonoma Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.6 M, whereas Return On Tangible Assets are forecasted to decline to (0.34).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.50 | 12.83 | |
| Tangible Book Value Per Share | 13.50 | 12.83 | |
| Enterprise Value Over EBITDA | 0.25 | 0.26 | |
| Price Book Value Ratio | 0.23 | 0.24 | |
| Enterprise Value Multiple | 0.25 | 0.26 | |
| Price Fair Value | 0.23 | 0.24 | |
| Enterprise Value | 5.1 M | 4.8 M |
The management team at Sonoma Pharmaceuticals has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 1.378 |
Basic technical analysis of Sonoma Stock
As of the 22nd of November, Sonoma Pharmaceuticals has the Risk Adjusted Performance of (0.02), coefficient of variation of (2,587), and Variance of 65.82. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sonoma Pharmaceuticals, as well as the relationship between them.Sonoma Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sonoma Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sonoma Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sonoma Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mclaughlin John over two months ago Acquisition by Mclaughlin John of 20000 shares of Sonoma Pharmaceuticals at 1.08 subject to Rule 16b-3 | ||
Schutz James J over three months ago Disposition of 28 shares by Schutz James J of Sonoma Pharmaceuticals at 70.35 subject to Rule 16b-3 | ||
Dal Poggetto John over three months ago Acquisition by Dal Poggetto John of 15000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Dal Poggetto John over six months ago Disposition of 1648 shares by Dal Poggetto John of Sonoma Pharmaceuticals at 175.5 subject to Rule 16b-3 | ||
Frederick Sandford over six months ago Acquisition by Frederick Sandford of 400000 shares of Sonoma Pharmaceuticals at 0.717 subject to Rule 16b-3 | ||
Bruce Thornton over six months ago Acquisition by Bruce Thornton of 60000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Bruce Thornton over a year ago Acquisition by Bruce Thornton of 100000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 |
Sonoma Pharmaceuticals' Outstanding Corporate Bonds
Sonoma Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sonoma Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sonoma bonds can be classified according to their maturity, which is the date when Sonoma Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Understand Sonoma Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sonoma Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 5.52 | |||
| Coefficient Of Variation | (2,587) | |||
| Standard Deviation | 8.11 | |||
| Variance | 65.82 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (1.38) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 40.82 | |||
| Value At Risk | (13.23) | |||
| Potential Upside | 13.88 | |||
| Skewness | 0.3263 | |||
| Kurtosis | 2.43 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 5.52 | |||
| Coefficient Of Variation | (2,587) | |||
| Standard Deviation | 8.11 | |||
| Variance | 65.82 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (1.38) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 40.82 | |||
| Value At Risk | (13.23) | |||
| Potential Upside | 13.88 | |||
| Skewness | 0.3263 | |||
| Kurtosis | 2.43 |
Consider Sonoma Pharmaceuticals' intraday indicators
Sonoma Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sonoma Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 50821.15 | |||
| Daily Balance Of Power | (0.20) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 2.99 | |||
| Day Typical Price | 2.94 | |||
| Price Action Indicator | (0.17) | |||
| Period Momentum Indicator | (0.06) |
Sonoma Pharmaceuticals Corporate Filings
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 20th of September 2024 Other Reports | ViewVerify | |
| 15th of August 2024 Other Reports | ViewVerify |
Sonoma Stock media impact
Far too much social signal, news, headlines, and media speculation about Sonoma Pharmaceuticals that are available to investors today. That information is available publicly through Sonoma media outlets and privately through word of mouth or via Sonoma internal channels. However, regardless of the origin, that massive amount of Sonoma data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sonoma Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sonoma Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sonoma Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sonoma Pharmaceuticals alpha.
Sonoma Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sonoma Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Sonoma Pharmaceuticals Corporate Management
| Jerome Dvonch | Interim Officer | Profile | |
| John Poggetto | Controller | Profile | |
| Victoria Covel | Assistant Controller | Profile | |
| Chad White | Interim Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 20.967 | Quarterly Revenue Growth (0.01) | Return On Assets (0.20) | Return On Equity (0.75) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Sonoma Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.